S. Ardigo and J. Philippe, Hypoglycémie et diabète, Rev Med Suisse, vol.4, pp.1376-1382, 2008.

N. Zamitt and B. Frier, Hypoglycemia in Type 2 Diabetes: Pathophysiology, frequency, and effects of different treatment modalities, Diabetes Care, vol.28, issue.12, pp.2948-2961, 2005.
DOI : 10.2337/diacare.28.12.2948

S. Ardigo and P. J. , Hypoglycémie et diabète Revue médicale suisse, pp.1376-1382, 2008.

L. Glasser, M. Alt-tebacher, and J. Schlienger, Iatrogenic hypoglycemias. Médecine des maladies métaboliques, pp.377-81, 2011.

I. Pierre, Hypoglycémies : principales étiologies et hypoglycémies iatrogènes Thèse d'exercice en pharmacie : Nancy : Université de Lorraine faculté de pharmacie, Disponible sur

N. White, D. Warrel, P. Chantavanich, S. Looareesuwan, M. Warrel et al., Severe Hypoglycemia and Hyperinsulinemia in Falciparum Malaria, New England Journal of Medicine, vol.309, issue.2, pp.61-67, 1983.
DOI : 10.1056/NEJM198307143090201

J. Sacareau, Hypoglycémies iatrogènes sévères chez les patients diabétiques de type 2 : Fréquence de survenue, circonstances et coûts médico-économiques, Thèse d'exercice en Pharmacie, 2012.

M. Mura, F. Coto-yglesias, A. Wang, N. Sheidaee, R. Mullan et al., Drug-Induced Hypoglycemia: A Systematic Review, The Journal of Clinical Endocrinology & Metabolism, vol.94, issue.3, pp.741-786, 2009.
DOI : 10.1210/jc.2008-1416

A. Sarayaa, M. Yokokuraa, T. Gonoib, and S. Seinoa, Effects of fluoroquinolones on insulin secretion and beta-cell, Science Direct. European Journal of Pharmacology, vol.497, 2004.

B. Inkster, M. Nicola, N. Zammitt, M. Frcpe-&-brian, M. Frier-bschons et al., Drug-induced hypoglycaemia in type 2 diabetes, Expert Opinion on Drug Safety, vol.46, issue.1, pp.597-614, 2012.
DOI : 10.1111/j.1463-1326.2006.00684.x

J. André and . Scheen, Utilisation des antidiabétiques oraux en cas d'insuffisance rénale, Rev Med Suisse, pp.1614-1620, 2012.

A. Wright, C. Cull, K. Macleod, and U. G. For-the, Hypoglycemia in Type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73, Journal of Diabetes and its Complications, vol.20, issue.6, pp.395-401, 2006.
DOI : 10.1016/j.jdiacomp.2005.08.010

G. Viberti, S. Kahn, and D. Greene, A Diabetes Outcome Progression Trial (ADOPT): An international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes, Diabetes Care, vol.25, issue.10, pp.1737-1780, 2002.
DOI : 10.2337/diacare.25.10.1737

P. Vexiau, P. Mavros, and G. Krishnarajah, Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France, Diabetes, Obesity and Metabolism, vol.19, issue.s1, pp.16-24, 2008.
DOI : 10.1210/jc.79.6.1659

G. Leese, J. Wang, and J. Broomhall, Frequency of Severe Hypoglycemia Requiring Emergency Treatment in Type 1 and Type 2 Diabetes: A population-based study of health service resource use, Diabetes Care, vol.26, issue.4, pp.1176-80, 2003.
DOI : 10.2337/diacare.26.4.1176

T. Seck, M. Nauck, and D. Sheng, Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study, International Journal of Clinical Practice, vol.287, issue.5, pp.562-76, 2010.
DOI : 10.1007/s00125-002-1009-0

G. Charpentier, F. Fleury, and M. Kabir, Improved glycaemic control by addition of glimepiride to metformin monotherapy in Type 2 diabetic patients, Diabetic Medicine, vol.281, issue.10, pp.828-862, 2001.
DOI : 10.1007/BF03348039

M. Marre, J. Shaw, and M. Brandle, Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26??weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type??2 diabetes (LEAD-1 SU), Diabetic Medicine, vol.284, issue.3
DOI : 10.1152/ajpendo.00315.2002

J. Lachérade, Les conséquences de l'hypoglycémie. Consequences of hypoglycemia, pp.437-441, 2008.

R. Gruetter, K. Ugurbil, and E. Seaquist, Steady-State Cerebral Glucose Concentrations and Transport in the Human Brain, Journal of Neurochemistry, vol.70, issue.1, pp.397-408, 1998.
DOI : 10.1046/j.1471-4159.1998.70010397.x

I. Choi, S. Lee, S. Kim, and R. Gruetter, Measurements of Brain Glucose Transport Using the Reversible Michaelis???Menten Model and Simultaneous Measurements of Cerebral Blood Flow Changes during Hypoglycemia, Journal of Cerebral Blood Flow & Metabolism, vol.33, issue.6, pp.653-63, 2001.
DOI : 10.1002/mrm.1910330310

S. Halimi, Acute consequences of hyperglycaemia in diabetic patients. Diabetes Metab, pp.75-83, 2010.

E. Seaquist, J. Anderson, B. Childs, P. Cryer, S. Dagogo-jack et al., Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society, Diabetes Care, vol.36, issue.5, pp.1384-95, 2013.
DOI : 10.2337/dc12-2480

G. Leese, J. Wang, and J. Broomhall, Frequency of Severe Hypoglycemia Requiring Emergency Treatment in Type 1 and Type 2 Diabetes: A population-based study of health service resource use, Diabetes Care, vol.26, issue.4, pp.1176-80, 2003.
DOI : 10.2337/diacare.26.4.1176

A. Holstein, O. Patzer, and K. Machalke, Substantial increase in incidence of severe hypoglycemia between: a German longitudinal populationbased study. Diabetes Care, pp.972-977, 1997.

D. Bonds, M. Miller, and J. Dudl, Severe hypoglycemia symptoms, antecedent behaviors, immediate consequences and association with glycemia medication usage: Secondary analysis of the ACCORD clinical trial data, BMC Endocrine Disorders, vol.27, issue.11, p.5, 2012.
DOI : 10.2337/diacare.27.11.2585

H. Gerstein, M. Miller, R. Byington, D. Goff, . Jr et al., Effects of intensive glucose lowering in type 2 diabetes, N Engl J Med, vol.358, issue.24, pp.2545-59, 2008.

D. Orozco-beltrán, P. Mezquita-raya, R. De-arellano, A. Galán, and M. , Self-Reported Frequency and Impact of Hypoglycemic Events in Spain, Diabetes Therapy, vol.24, issue.Suppl 1, pp.155-168, 2014.
DOI : 10.1016/j.jdiacomp.2009.07.006

N. Chevalier, P. Böhme, and A. Durand-lugger, Incidence, predictive factors and direct costs of severe hypoglycemia-results from the prospective 104, EASD, 2015.

R. Mccoy, . Lipska, . Yao, N. Van-houten, and . Shah, Glycemic Overtreatment and Severe Hypoglycemia among Adults with Non-insulin-requiring Type 2 Diabetes, DIABETES, p.2015

B. Quilliam, J. Simeone, A. Ozbay, and S. Koqut, The incidence and costs of hypoglycemia in type 2 diabetes, Am J Manag Care, vol.17, issue.10, pp.673-80, 2011.

>. Invs, . Le, and E. Etude, Disponible sur : http://www.invs.sante.fr/Dossiers-thematiques/Maladies-chroniques-et- traumatismes, 2007.

I. Robert-bobée, Projections de population 2005-2050 Vieillissement de la population en France métropolitaine Disponible sur

M. Kazem and F. Ye, Mehul Dalal : incidence of hypoglycaemia in patients with type 2 diabetes mellitus recently initiating basal insulin in a real-world us setting

D. Owens, S. Luzio, and I. Ismail, Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes, Diabetes Care, vol.23, issue.4, pp.518-541, 2000.
DOI : 10.2337/diacare.23.4.518

P. Vexiau, P. Mavros, G. Krishnarajah, R. Lyu, and D. Yin, Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France, Diabetes, Obesity and Metabolism, vol.19, issue.s1, pp.16-24, 2008.
DOI : 10.1210/jc.79.6.1659

A. Holstein, Severe sulfonylurea-induced hypoglycemia: a problem of uncritical prescription and deficiencies of diabetes care in geriatric patients, Expert Opinion on Drug Safety, vol.106, issue.51, pp.675-81, 2010.
DOI : 10.1111/j.1463-1326.2009.01051.x

F. Zaccardi, M. Davies, and N. Dhalwani, Trends in hospital admissions for hypoglycaemia in England: a retrospective, observational study, The Lancet Diabetes & Endocrinology, vol.4, issue.8, pp.677-85, 2016.
DOI : 10.1016/S2213-8587(16)30091-2

C. Bettina-köhler-ballan, L. Tran, U. M. Perrenoud, and . Vischer, Hypoglycémie sévère chez le patient diabétique de type 2 âgé : quelle prévention, Rev Med Suisse, pp.2166-2169, 2011.

M. Tancredi, Excess Mortality among Persons with Type 2 Diabetes, New England Journal of Medicine, vol.373, issue.18, pp.1720-1732, 2015.
DOI : 10.1056/NEJMoa1504347

S. Inzucchi, R. Bergenstal, J. Buse, M. Diamant, E. Ferrannini et al., Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), Diabetologia, vol.290, issue.Suppl 2, pp.1577-96, 2012.
DOI : 10.1001/jama.290.4.486

U. Pedersen-bjergaard, S. Pramming, and B. Thorsteinsson, Recall of severe hypoglycaemia and self-estimated state of awareness in type 1 diabetes, Diabetes/Metabolism Research and Reviews, vol.38, issue.3, pp.232-240, 2003.
DOI : 10.7326/0003-4819-134-9_Part_1-200105010-00009

D. Clerc, O. Hugli, L. Trueb, and B. Yersin, Place de l'octréotide dans le traitement des hypoglycémies induites par les sulfonylurées, Revue Medicale Suisse, vol.4, pp.1764-67, 2008.

Y. Gao, K. Yoon, and L. Chuang, Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea, Diabetes Research and Clinical Practice, vol.83, issue.1, pp.69-76, 2009.
DOI : 10.1016/j.diabres.2008.09.037